Q2 miss should not be a major concern
08/08/25 -"The Q2 results fell short of consensus, as growth in Life Science and Healthcare was materially offset by weakness in the Electronics business. However, the management slightly upgraded the adjusted ..."
Pages
80
Language
English
Published on
08/08/25
You may also be interested by these reports :
08/08/25
H1 results surpassed expectations, driven by a healthy performance from the Injectables segment. Also, the management reiterated its full-year ...
08/08/25
Genmab’s Q2 results exceeded market expectations, driven by strong performance across key offerings, resulting in significant profitability growth. ...
08/08/25
The Q2 results fell short of consensus, as growth in Life Science and Healthcare was materially offset by weakness in the Electronics business. ...
07/08/25
The Q2/H1 results exceeded expectations, putting the firm on track towards achieving its full-year targets. As expected, Biosimilars drove the show, ...